GB9825632D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB9825632D0
GB9825632D0 GBGB9825632.4A GB9825632A GB9825632D0 GB 9825632 D0 GB9825632 D0 GB 9825632D0 GB 9825632 A GB9825632 A GB 9825632A GB 9825632 D0 GB9825632 D0 GB 9825632D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9825632.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB9825632.4A priority Critical patent/GB9825632D0/en
Publication of GB9825632D0 publication Critical patent/GB9825632D0/en
Priority to EP99972545A priority patent/EP1131098A1/en
Priority to JP2000583562A priority patent/JP2002530354A/ja
Priority to AU13846/00A priority patent/AU1384600A/en
Priority to PCT/EP1999/008988 priority patent/WO2000030679A1/en
Priority to US09/862,212 priority patent/US20010041179A1/en
Priority to US12/180,660 priority patent/US20080286281A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9825632.4A 1998-11-23 1998-11-23 Organic compounds Ceased GB9825632D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB9825632.4A GB9825632D0 (en) 1998-11-23 1998-11-23 Organic compounds
EP99972545A EP1131098A1 (en) 1998-11-23 1999-11-22 Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation
JP2000583562A JP2002530354A (ja) 1998-11-23 1999-11-22 移植の拒絶反応の出現の処置に使用するためのｃｄ２５結合分子
AU13846/00A AU1384600A (en) 1998-11-23 1999-11-22 Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation
PCT/EP1999/008988 WO2000030679A1 (en) 1998-11-23 1999-11-22 Cd25 binding molecules for use in the treatment of manifestations of rejection in transplantation
US09/862,212 US20010041179A1 (en) 1998-11-23 2001-05-22 CD25 binding molecules for use in the treatment of manifestations of rejection in transplantation
US12/180,660 US20080286281A1 (en) 1998-11-23 2008-07-28 Cd25 binding molecules for the use in the treatment of manifestations of rejection in transplantation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825632.4A GB9825632D0 (en) 1998-11-23 1998-11-23 Organic compounds

Publications (1)

Publication Number Publication Date
GB9825632D0 true GB9825632D0 (en) 1999-01-13

Family

ID=10842889

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9825632.4A Ceased GB9825632D0 (en) 1998-11-23 1998-11-23 Organic compounds

Country Status (6)

Country Link
US (2) US20010041179A1 (enExample)
EP (1) EP1131098A1 (enExample)
JP (1) JP2002530354A (enExample)
AU (1) AU1384600A (enExample)
GB (1) GB9825632D0 (enExample)
WO (1) WO2000030679A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US8252126B2 (en) * 2004-05-06 2012-08-28 Global Advanced Metals, Usa, Inc. Sputter targets and methods of forming same by rotary axial forging
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3815472A1 (de) * 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
ATE222502T1 (de) * 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Also Published As

Publication number Publication date
JP2002530354A (ja) 2002-09-17
WO2000030679A1 (en) 2000-06-02
US20010041179A1 (en) 2001-11-15
AU1384600A (en) 2000-06-13
EP1131098A1 (en) 2001-09-12
US20080286281A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
GB9811854D0 (en) Organic compounds
GB9802251D0 (en) Organic compounds
GB9802249D0 (en) Organic compounds
GB9825632D0 (en) Organic compounds
GB9804265D0 (en) Organic compounds
GB9802355D0 (en) Organic compounds
GB9804742D0 (en) Organic compounds
GB9801866D0 (en) Organic compounds
GB9802842D0 (en) Organic compounds
GB9802450D0 (en) Organic compounds
GB9803324D0 (en) Organic compounds
GB9802252D0 (en) Organic compounds
GB9803904D0 (en) Organic compounds
GB9801539D0 (en) Organic compounds
GB9805199D0 (en) Organic compounds
GB9803907D0 (en) Organic compounds
GB9801469D0 (en) Organic compounds
GB9801206D0 (en) Organic compounds
GB9800701D0 (en) Organic compounds
GB9800520D0 (en) Organic compounds
GB9800316D0 (en) Organic compounds
GB9800195D0 (en) Organic compounds
GB9804494D0 (en) Organic compounds
GB9804577D0 (en) Organic compounds
GB9810242D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)